M&A

M&A

Marksans acquires capacity from Goa-bsed Tevapharm

BSE Disclosure  

Publicly listed Marksans Pharma Ltd is to acquire the business relating to the manufacture and supply of bulk pharmaceutical formulations from Goa-based Tevapharm India Pvt Ltd for cash, as a going concern on a slump sale basis. Marksans would retain the site employees. Torreya acted as the exclusive financial advisor to Marksans Pharma Limited on their acquisition. The transaction is expected to be finalized by April 1, 2023. Teva's affiliate Watson Pharma Pvt Ltd will continue to own and operate its other manufacturing site in Goa. Marksans plans to manufacture tablets, hard and soft gel capsules, ointments, gummies, creams, from the new capacity. The manufacturing site is spread across 47,597 square meters and has approvals to manufacture products from EU, Health Canada & Japanese Health Authority.